九九人人综合网,草性感熟妇

ASCO 2025: Multiple Domestic New Drugs Reveal Impressive Clinical Data ASCO ASCO 2025 highlights impressive clinical data from multiple domestic new drugs including Kelun Biotech's sacituzumab govitecan, Mabwell's 9MW2821, Zelgen Bio's ZG006, and Hengrui's SHR-1501, showing promising efficacy and safety.
ASCO 2025: Innovent, RemeGen, Kelun Showcase Together! ASCO ASCO 2025 highlights: Leading Chinese biotech companies Xinda, Rongchang, and Kelun present innovative clinical trial data on ADCs, bispecific antibodies, and targeted therapies, showcasing China's rising role in oncology innovation.
ASCO 2025: Most-Viewed Abstracts ASCO Discover the top 4 most viewed abstracts at ASCO 2025, including updates on zanidatamab, talazoparib, GFH375, and Ziftomenib across gastric, prostate, solid tumors, and AML research.
ASCO 2025: Top 10 Clinical Breakthrough Oncology Products with Key Trial Results ASCO Discover the top 10 clinical breakthrough oncology products presented at ASCO 2025, featuring innovative therapies from leading companies with promising efficacy and safety data in advanced cancers.
2025 ASCO: Chinese Pharma Innovations in Lung, Gastric, Blood & Thyroid Cancer Treatments ASCO 2025 ASCO abstracts highlight breakthroughs by Chinese pharmaceutical companies across lung, gastric, hematologic, and thyroid cancers, showcasing innovation in targeted and combination therapies.
AkzoNobel Continues Investing in China Despite Closing Two More Plants AkzoNobel AkzoNobel closes two European plants but boosts investment in China, expanding capacity in wind power, marine, and high-performance coatings, highlighting confidence in China's growing market.
Top 10 Best-Selling Drugs in Q1 2025 Market Trend Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
Pharma's $158B U.S. Manufacturing Surge Market Trend Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Q1 Sales Surge for CAR-T Therapies: Up to 146% Market Trend GuideView reviews the Q1 2025 sales performance of six FDA-approved CAR-T cell therapies. Highlights include Breyanzi’s 146% surge and Carvykti’s 135% rise, while Kymriah and Tecartus saw declines.
Takeda's 2024 Financial report Market Trend Takeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.

< Pre 1...17 18 192021 22 23...26 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水